GM-2505

GM-2505 (bretisilocin) is a short-duration intravenous 5-HT2A receptor agonist originally developed by Gilgamesh Pharmaceuticals for major depressive disorder. The Phase 2a study (NCT06236880) reported positive topline results in mid-2025, with the 10 mg dose producing a -21.6 point MADRS change vs -12.1 for a 1 mg low-dose psychoactive comparator at Day 14 (p=0.003), and a 94% remission rate at Day 29 in the high-dose group [2][7]. In August 2025, AbbVie announced an agreement to acquire bretisilocin for up to $1.2 billion, expanding an earlier collaboration (May 2024: $65M upfront plus up to $1.95B in option fees and milestones) [5][8]. The thesis: compress the psychedelic dosing session from 4-6 hours (oral psilocybin) to roughly 60-90 minutes of subjective effects, which would collapse the clinic-bed time that has bottlenecked psychedelic therapy economics [9].

GM-2505 (bretisilocin) is a novel small molecule, never approved anywhere. Phase 2a topline results from NCT06236880 were announced in mid-2025 and were positive on both safety and the secondary MADRS efficacy endpoint [2][7]. A first-in-human pharmacokinetic and safety paper by Marek et al. published in J Psychopharmacol in 2025 (Sage Journals) showed the compound is tolerated in healthy volunteers, with t1/2 of 40-50 minutes and dose-proportional Cmax and AUC [9]. The original PMID cited in earlier drafts (41099491) could not be verified through standard PubMed lookup at the time of revision and is replaced with the DOI-anchored citation. No FDA breakthrough, fast track, or orphan designations have been publicly disclosed. The most material status point is commercial: in May 2024, AbbVie and Gilgamesh signed a $65M-upfront collaboration with up to $1.95B in option fees and milestones [5]; in August 2025, AbbVie announced an agreement to acquire bretisilocin outright for up to $1.2 billion, including an upfront payment and contingent milestones [8]. AbbVie's 2026 10-K continues to reference its investment in next-generation neuropsychiatry assets [3]. No public Phase 3 initiation date has been disclosed at the time of writing.

Serotonin 2A receptors (HTR2A) sit on the surface of cortical neurons, especially on prefrontal cortex pyramidal cells that organize mood, cognition, and self-referential thinking [6]. When a psychedelic such as psilocybin or LSD activates these receptors, the affected neurons fire in unusual patterns. The leading hypothesis: this transient hyperactivation rewires how brain regions communicate, breaking entrenched negative loops that keep depressed patients stuck. GM-2505 is a substituted tryptamine-class small molecule (per patent filings and Gilgamesh disclosures) administered as an IV infusion, with secondary serotonin-releaser activity to its primary 5-HT2A agonism [9][10]. The pharmacokinetic basis for the compressed duration is straightforward: intravenous dosing bypasses oral absorption variability and avoids the hepatic first-pass conversion of psilocybin to its active metabolite psilocin, allowing more precise control of peak exposure and a faster decline. Published Phase 1 data show a plasma t1/2 of roughly 40-50 minutes, which lines up with the reported 60-90 minute window of subjective effects, versus the 4-6 hour experience typical of oral psilocybin [9]. Whether the shorter duration is additionally tuned by receptor binding kinetics versus pure clearance has not been disclosed in public sources. The target validation is real but partial. Open-label and randomized psilocybin trials show rapid, durable antidepressant effects in treatment-resistant depression that look qualitatively different from SSRIs. Compass Pathways' COMP360, a synthetic psilocybin, hit its primary endpoint in a Phase 2b TRD trial and is now in Phase 3 [4]. Open Targets ranks HTR2A as a high-evidence serotonin receptor target for MDD [6]. So the receptor is a credible mood mechanism. The harder, originally unresolved question - whether 5-HT2A agonism without the long subjective trip carries the same antidepressant benefit - is what the GM-2505 Phase 2a directly addressed; the positive topline is the first prospective signal that compressed-duration dosing can produce a clinically meaningful effect.

NCT06236880 was a Phase 2a study sponsored by Gilgamesh Pharmaceuticals [2]. The Phase 2a Part A randomized, double-blind cohort (n=40 per the 2025 topline release) compared a 10 mg IV dose of GM-2505 against a 1 mg low-dose psychoactive comparator of the same compound - a design choice that materially addresses functional unblinding, the chronic problem in psychedelic trials where patients almost always know whether they received drug or placebo. Using a low active dose as the control preserves a subjective dosing experience in both arms, which is a methodological strength the field has been moving toward [7]. The primary endpoint was safety and tolerability, with MADRS change from baseline as the key efficacy readout. Topline results: -21.6 point MADRS reduction in the 10 mg arm vs -12.1 in the 1 mg comparator arm at Day 14 (p=0.003), with 70% MADRS remission at Day 14 and 94% remission at Day 29 in the high-dose group following an additional 15 mg dose [7]. The total recruiting target across all three parts of the protocol was 124, but the Part A topline that supported the AbbVie acquisition was based on a 40-patient cohort. Caveats: n=40 is small; remission rates this high almost always compress in larger trials; durability beyond Day 29 was not part of the topline; and even with a low-dose active control, full unblinding cannot be ruled out at this scale. Phase 3 will be the true test.

The model gives this drug a 4% chance of eventually being approved. That number starts from the historical approval rate for Phase 2 drugs in this area, which is about 24%, then adjusts based on ten facts about the trial and its sponsor. The biggest factors pulling the estimate down are heavier-than-usual blinding, the sponsor's thin or weak approval record, weak earlier-phase results, and a randomized trial design. The remaining factors were close to average for this stage and did not shift the estimate much.

Efficacy risk is now substantially reduced versus the pre-2025 picture, but not eliminated. The Phase 2a topline is positive and statistically significant against an active comparator, which is the right control choice for this class. Two concerns remain. First, n=40 is small and remission rates near 94% essentially never replicate at full scale. Second, durability beyond Day 29 was not part of the topline; if benefits compress to weeks rather than months, the cost-effectiveness story weakens. Safety risk is moderate. 5-HT2A agonists transiently raise blood pressure and heart rate, and intravenous dosing produces an acute exposure peak that differs sharply from oral psilocybin pharmacokinetics [9]. Cardiac monitoring is mandatory during dosing sessions. Chronic 5-HT2B activation has historically been linked to valve toxicity (the fen-phen problem), but acute single-dose IV exposure makes this less of a concern than chronic ergotamine-style toxicity. Execution risk centers on functional unblinding, which has dogged every psychedelic trial in this field. The 1 mg active comparator design helps but does not fully eliminate the risk that patients identify their arm. Commercial risk is structural. Even if approved, in-clinic IV administration requires reimbursement for chair time, qualified supervision, and infrastructure that few practices currently offer. Spravato (esketamine nasal spray, Janssen) demonstrated payer willingness to reimburse supervised in-clinic administration of a psychoactive drug - a structurally similar reimbursement challenge, though nasal delivery differs from IV. Gilgamesh has disclosed plans for an intramuscular formulation in future studies, which could broaden the administration footprint. Compass Pathways' COMP360 may still reach market first if its Phase 3 succeeds, setting pricing and access benchmarks GM-2505 must beat [4].

Materially de-risked since the original writeup was drafted. GM-2505 (bretisilocin) hit its Phase 2a topline in mid-2025 with a -21.6 MADRS reduction vs -12.1 for a low-dose active control (p=0.003) and 94% Day 29 remission in n=40 [7], and AbbVie announced an agreement to acquire the program in August 2025 for up to $1.2 billion [8]. That sequence collapses two of the biggest pre-readout uncertainties: efficacy signal at the compressed duration, and capital to fund Phase 3. The remaining watch items are (1) Phase 3 trial initiation and design - particularly whether AbbVie keeps the low-dose active comparator and extends durability assessment well past Day 29 - and (2) deal close timing and any subsequent AbbVie disclosures on portfolio prioritization (the 2026 10-K and quarterly calls remain the most accessible source while integration proceeds) [3]. Note that 'MDD' and 'TRD' are distinct indications: MDD (major depressive disorder) is the broader patient population the GM-2505 Phase 2a enrolled (patients not currently taking antidepressants), while TRD (treatment-resistant depression) - typically defined as failure of two or more adequate antidepressant trials - is the narrower indication where psilocybin programs like COMP360 have generated the strongest existing evidence base. The class context now sharpens: MindMed's MM-120 (lysergide d-tartrate, in Phase 3 for generalized anxiety disorder and a Phase 3 program in MDD) and Cybin's CYB003 (a deuterated psilocin analog, in Phase 3 for MDD) are GM-2505's most relevant short-duration / next-gen competitors. Compass Pathways' COMP360 remains the closest-to-market comparator if its Phase 3 reads out first.